Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.75 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.75 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.47 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.47 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425018 | 1.00 | ITGB3 (0.75) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL8650015 | 0.89 | ITGB3 (0.73) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL5820899 | 0.88 | ITGB3 (0.67) | ITGB3ITGA2BCA1CA2CYP51A1 | |
| SCHEMBL7291927 | 0.87 | ITGB3 (0.62) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL13933091 | 0.87 | ITGB3 (0.83) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL8020868 | 0.87 | ITGB3 (0.75) | ITGB3ITGA2BF2PLGPRSS1 | |
| Lamifiban SCHEMBL871446 | 0.86 | ITGB3 (1.00) | ITGB3ITGA2BF2PLGPRSS1 | |
| Lamifiban SCHEMBL4683 | 0.86 | ITGB3 (1.00) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL8689958 | 0.85 | ITGB3 (0.73) | ITGB3ITGA2BF2PLGPRSS1 | |
| SCHEMBL6099288 | 0.84 | ITGB3 (0.57) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109326-B2 | Halo-alkoxycarbonyl prodrugs | GENENTECH, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-0975608-B1 | HALO-ALKOXYCARBONYL PRODRUGS | GENENTECH INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040220401-A1 | Novel halo-alkoxycarbonyl prodrugs | GENENTECH, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20010020019-A1 | NOVEL HALO-ALKOXYCARBONYL PRODRUGS | GENENTECH, INC. | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220401-A1 | Novel halo-alkoxycarbonyl prodrugs | PNP, PAICS, PHOSPHO1 | ITGB3 2194/4885ITGA2B 3070/4885F2 4407/4885 |
| US-20010020019-A1 | NOVEL HALO-ALKOXYCARBONYL PRODRUGS | PNP, PAICS, PHOSPHO1 | ITGB3 2194/4885ITGA2B 3070/4885F2 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.